Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
about
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsGastroenteropancreatic high-grade neuroendocrine carcinomaClinical utility of lanreotide AutogelĀ® in gastroenteropancreatic neuroendocrine tumorsThe biological characterization of neuroendocrine tumors: the role of neuroendocrine markersA new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumoursChromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytomaOne Year Follow-Up Risk Assessment in SKH-1 Mice and Wounds Treated with an Argon Plasma Jet.Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumorsENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumorsNew markers for pancreatic islets and islet cell tumors.Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms.Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion.Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.Gastroenteropancreatic endocrine tumors: clinical characterization before therapy.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.Response of gastric epithelial progenitors to Helicobacter pylori Isolates obtained from Swedish patients with chronic atrophic gastritis.Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers.Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma.Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.Chromogranin A as a valid marker in oncology: Clinical application or false hopes?Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patientsElevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.Characterization of serum and urinary chromogranin A by size exclusion chromatography: impact on calibrator selection and urinary assay.Poorly Differentiated Neuroendocrine Tumor of the Esophagus with Hypertrophic Osteoarthropathy and Brain Metastasis: A Success Story.Chromogranin A as serum marker of pituitary adenomas.Chromogranin 'A' in normal subjects, essential hypertensives and adrenalectomized patients.Relationship between renal function and blood level of chromogranin A.Serum chromogranin-A in advanced prostate cancer.Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.[A 64-year-old female patient with recurring hypoglycaemia. Difficult aspects of diagnosis].Identification of Differentiation-Related Proteins in Gastric Adenocarcinoma Tissues by Proteomics.Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation.
P2860
Q26996521-D522FD1A-FA35-486D-A18F-F89CCD98987CQ26998392-73F10FC7-BC57-4EDE-9736-531E54043FEBQ28069632-B56D70D3-3309-4C3B-809B-488C843458A4Q28275872-480E4E1D-5EA2-412C-BA7D-3703422DF2AAQ28359544-ACF692D9-4C06-4F01-B164-4A87C362F569Q28360892-3CE78708-47B2-4F52-A98B-F9CC94F81518Q33624923-BD19B226-7AEB-4A9E-ACEA-AB2F875D3811Q33879192-B5312C7D-0561-4E3A-A89E-4FE3BC83F50FQ34248466-D31679E2-4E60-4212-8315-99DE1ADE3AA7Q34573558-39903067-D8DD-401E-911B-7DD643B4CEEEQ34776429-C48D3546-76F0-467A-A60D-FF1B73A381CAQ34810946-63A1C197-6737-45BF-A45A-43077CC624B5Q35493206-2321187F-BA7D-48C0-BD1F-4CAA90DF56BEQ35713515-4E4F0D39-8297-4D4E-AFAF-4DE94CB8064CQ35939961-5DE2C5CC-5BD9-40FD-82E1-9272D9BC0366Q36620016-AA56F6F3-F9B0-4C5E-AF9E-1B25323D8CB2Q36742033-0793CB99-9D78-4F9E-A333-8AED96F18374Q37201458-2ACCD4E6-BFFF-405E-A7A0-0CE94171AF40Q37431748-59C5088C-D7A5-4DA7-8143-3C45F0E03949Q37578830-33E08D25-7E59-45D6-9379-3206795FE51FQ37662137-39311317-A029-4C35-8D9C-C57434BEA004Q38014495-3C22B1A7-7CA4-4652-9E07-59B5FC76409CQ38843394-53C041B7-5411-4AFE-8C68-4939DDA46470Q38852179-B37036F6-B87B-40A9-8FF0-863A999A1D6EQ38923020-692A401D-59C6-48B6-8035-D95B9920C505Q38931272-D3A9371A-E0F9-473A-8F80-050CF538AD3BQ39152232-5A113C01-59AD-4256-BB58-F61AF6780951Q40795001-55DFF4FA-8BC4-46EE-9630-20BCDD065D6BQ41863208-E3DCE163-93DD-4190-BCE6-099E624E3DB3Q42452799-9BC32098-B8C5-4A43-AEA4-E2B0DEA18671Q42523235-8E8E7998-0070-40B2-B406-D3F9E31A9DF5Q43703519-4FFB7FDF-D263-4C99-B1FB-092889477678Q43914900-999EBE5F-53C7-4BE9-89F4-3526459EA8CDQ44425475-4DDFC6A7-6650-43FB-8587-2A9B23A0CE08Q44856223-D4F54DE9-5298-44EB-A190-D1FD5447C266Q47852720-97ED11D7-B66E-4BD2-A8EE-BEC3C97A7EDBQ49179899-DED1F9F8-1545-4B14-A937-30F52B542494Q51465427-4A8FA87C-AC7A-40D6-A4D3-C3E77252EF5BQ51510767-FF110DA3-E327-4CB9-BFD7-29258BB4994DQ51838966-D2DC7ADB-F3FF-43BF-868E-DBC996931613
P2860
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
description
1998 nĆ® lÅ«n-bĆ»n
@nan
1998幓ć®č«ę
@ja
1998幓å¦ęÆęē«
@wuu
1998幓å¦ęÆęē«
@zh-cn
1998幓å¦ęÆęē«
@zh-hans
1998幓å¦ęÆęē«
@zh-my
1998幓å¦ęÆęē«
@zh-sg
1998幓åøč”ęē«
@yue
1998幓åøč”ęē«
@zh
1998幓åøč”ęē«
@zh-hant
name
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@ast
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@en
type
label
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@ast
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@en
prefLabel
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@ast
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@en
P2093
P2860
P356
P1476
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
@en
P2093
Cailleux AF
Gigliotti A
Sabourin JC
P2860
P2888
P304
P356
10.1038/BJC.1998.635
P407
P577
1998-10-01T00:00:00Z
P5875
P6179
1011165726